Donaldson Company Acquires Isolere Bio
February 21, 2023
Donaldson Company, Inc. acquired Isolere Bio, an early-stage biotechnology developer of IsoTag reagents and affinity-phase separation processes for purification of viral vectors and other biopharmaceuticals. The deal expands Donaldson's Life Sciences capabilities and will allow Isolere's technology to be commercialized and reported within Donaldson's Life Sciences segment.
- Buyers
- Donaldson Company, Inc.
- Targets
- Isolere Bio, Inc.
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Donaldson Company Acquires Purilogics
June 14, 2022
Biotechnology
Donaldson Company, Inc. (NYSE: DCI) has acquired Purilogics, LLC, an early-stage biotechnology developer of membrane chromatography products, for an initial purchase price of approximately $20 million plus milestone-based earnouts. The acquisition brings Purilogics' membrane purification technology into Donaldson's Industrial Filtration Solutions business to accelerate commercialization and expand Donaldson's life sciences capabilities.
-
Bio-Rad Acquires Celsee, Inc.
April 9, 2020
Biotechnology
Bio-Rad Laboratories has acquired Celsee, Inc., a developer of instruments and consumables for single-cell isolation, detection and analysis. The acquisition expands Bio‑Rad’s capabilities in single-cell analysis and precision medicine; terms were not disclosed.
-
Bionano Genomics Acquires Purigen Biosystems
November 28, 2022
Biotechnology
Bionano Genomics agreed to acquire Purigen Biosystems to integrate Purigen's isotachophoresis (ITP) Ionic Purification System into Bionano's optical genome mapping (OGM) workflow, aiming to simplify ultra-high molecular weight (UHMW) DNA isolation and address difficult sample types. The deal consideration is up to $64 million (including $32 million cash at closing and milestone-contingent payments) and was expected to close by December 8, 2022.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
-
BioCheck, Inc. Acquires DRG International, Inc.
August 18, 2021
Medical Devices
BioCheck, Inc. has acquired DRG International, Inc., a manufacturer of clinical diagnostic ELISAs and the DRG:HYBRiD-XL automated analyzer. The deal combines BioCheck's chemiluminescent assay development and automation platform with DRG's R&D, manufacturing and global distribution network to accelerate development and global scale-up of advanced clinical and research diagnostic tests.
-
Danaher Acquires Aldevron for $9.6 Billion
June 17, 2021
Biotechnology
Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.